K.H. Katsanos

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

Herma H. Fidder, Fabian Schnitzler, Marc Ferrante et al. · Gut · 2008 · 448 citations

Veterinary Medicine, Immunology, Pharmacotherapy +11

Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort

Zsuzsanna Végh, Johan Burisch, Natalia Pedersen et al. · Journal of Crohn s and Colitis · 2014 · 105 citations · Full text

Medicine, Health Sciences, Clinical Epidemiology +10

The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab

Uri Kopylov, Gerassimos J. Mantzaris, K.H. Katsanos et al. · Alimentary Pharmacology & Therapeutics · 2010 · 90 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease — An ECCO-EpiCom study^☆

Johan Burisch, Petra Weimers, N. Pedersen et al. · Journal of Crohn s and Colitis · 2014 · 73 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +10

Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort

Zsuzsanna Végh, Johan Burisch, N Pedersen et al. · Journal of Crohn s and Colitis · 2015 · 40 citations · Full text

Medicine, Clinical Sciences, Surgery +10